1.41
1.41 (0%)
As of Apr 28, 2025
Sellas Life Sciences Group, Inc. [SLS]
Source:
Company Overview
Sellas Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (646) 200-5278 |
| Industry | manufacturing |
| CEO | Angelos M. Stergiou |
| Website | www.sellaslifesciences.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-31.5 |
| Net Income | $-30.9 |
| Net Cash | $11.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -240.8% |
| Profit as % of Stockholder Equity | -326.3% |
Management Effectiveness
| Return on Equity | -326.3% |
| Return on Assets | -158.9% |
| Turnover Ratio | |
| EBITA | $-31.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $19.4 |
| Total Liabilities | $10 |
| Operating Cash Flow | $-35.4 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $46.8 |
